ClinicalTrials.gg
Not yet recruitingNCT07486453Updated Mar 20, 2026

Bioequivalence Study of Sacubitril Alisartan Amlodipine Tablets

A Phase 1 interventional study of Sequence A T-R-T-R and Sequence B R-T-R-T in Primary Hypertension, sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-20.

Sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 6 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 76 studies in Essential Hypertension with a site in China — 19 open to participants now, 20 under way, 2 of them phase 3. Essential Hypertension · China.

Planned enrollment
56th of 67
60 · median 297
Started
2026
with 5 others
Phase 1
6 of 76
3 open now
Primary completion
2026-04
later than 6 of 19 live
Registered
68th of 76
by date
Lead sponsor
5 of 76
Shenzhen Salubris Pharmaceuticals Co., Ltd.

Among the 76 studies in Essential Hypertension with a site in China, this one is the 56th largest by planned enrollment of the 67 interventional ones that give a count, is one of 6 that started in 2026, is one of 6 in phase 1, reaches primary completion later than 6 of the 19 other live ones, and was the 68th registered.

Essential Hypertension

481 studies on the registry are indexed under Essential Hypertension; 75 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

19 of the 76 studies in Essential Hypertension with a site in China are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 43 Essential Hypertension studies recruiting now, 15 (35%) set no upper age limit and 20 (47%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Essential Hypertension with a site in China, or all of them as a file.
02

Study summary

This study aims to evaluate the bioequivalence and safety of single oral administration of Sacubitril/Valsartan/Amlodipine Tablets (240mg/5mg) versus Sacubitril/Valsartan Calcium Tablets (240mg) combined with Amlodipine Besylate Tablets (5mg) in healthy adult study participants.

Read the detailed description

This study is a single-center, randomized, open-label, single oral dose, two-formulation, two-sequence, four-period, fully replicated crossover bioequivalence study designed to compare the bioequivalence of single oral administration of Sacubitril/Valsartan/Amlodipine Tablets (240mg/5mg) versus Sacubitril/Valsartan Calcium Tablets (240mg) combined with Amlodipine Besylate Tablets (5mg) in healthy adult participants.

03

Conditions studied

  • Primary Hypertension
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Study participants aged 18 to 60 years (inclusive of 18 and 60 years), both male and female
  • Body weight not less than 50 kg. (BMI) = weight (kg) / height\^2 (m\^2). BMI must be within the range of 19 to 26 kg/m\^2 (inclusive of the limit values)
  • The study participant is able to communicate well with the research staff, fully understand the purpose and requirements of this trial, voluntarily participate in the clinical trial, and sign a written form
  • The study participant or their partner has no plans for pregnancy, sperm donation, or egg donation during the study period and for 3 months after drug administration, and must agree to use at least one acceptable effective method
  • During the screening period: 110 mmHg ≤ seated systolic blood pressure (SBP) \< 140 mmHg, 65 mmHg ≤ seated diastolic blood pressure (DBP) \< 90 mmHg, and no orthostatic hypotension.

Exclusion criteria

Exclusion Criteria:

  • Those who smoked more than 5 cigarettes per day on average in the 3 months prior to the trial and are unable to quit smoking during the trial period.
  • Pregnant or breastfeeding women, or female study participants of with a positive blood pregnancy screening.
  • Known allergic reaction to angiotensin II receptor antagonists (such as sacubitril/valsartan sodium, alisartan ester, losartan, valsartan) and calcium channel blockers (such as nifedipine, amlodipine), or their ; or allergic constitution (multiple drug and food allergies).
  • Alcoholics or those who frequently consumed alcohol within the 3 months prior to screening, i.e., consuming more than 14 standard alcohol units per week (1 unit alcohol = 360 mL beer or 45 mL spirits with 40% alcohol content or 150 mL wine), or those with a positive alcohol breath test, or those unable to stop using any alcohol-containing products during the trial period.
  • Those who donated blood or experienced significant blood loss (>400 mL), used blood products, or received a blood transfusion within the three months prior to screening.
  • Those who have undergone surgery within 3 months prior to screening or plan to undergo surgery during the study period, or subjects with a history of surgery affecting drug absorption, distribution, metabolism, or excretion.
  • Those who have been vaccinated within 3 months prior to screening.
  • History of hypotension, syncope, needle fainting, swallowing difficulties, any gastrointestinal disease affecting drug absorption, or any history of conditions increasing hemorrhagic risk, such as acute gastritis or gastroduodenal ulcers.
  • Use of any drug that alters hepatic enzyme () activity or inhibitors of transporters (OAT1/3, OATP1B1/3) within 28 days prior to screening.
  • Use of any prescription drugs, over-the-counter medications, vitamin products, or herbal remedies within 14 days prior to screening.
  • Participation in any drug clinical trial and administration of any other drug, or use of investigational products, within 3 months prior to taking the study drug.
  • abnormalities in vital signs, physical examination, 12-lead (ECG), or laboratory tests (including complete blood count, urinalysis, blood biochemistry, coagulation profile, and four infectious disease markers) at screening.
  • Any other disease or medical history considered by the investigator as unsuitable for participation in this study, such as disorders of the central nervous, cardiovascular, digestive, respiratory, urinary, hematopoietic, immune systems, psychiatric conditions, or metabolic abnormalities.
  • Consumption of chocolate, any caffeine-containing, or xanthine-rich foods or beverages within 48 hours prior to taking the study drug.
  • History of drug abuse or substance abuse, or a positive urine drug screen at screening.
  • Those with special dietary habits who cannot comply with the unified dietary requirements, or those with lactose intolerance (e.g., history of diarrhea after drinking milk).
  • Any other reason considered by the investigator as unsuitable for enrollment.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Sequence A T-R-T-R

    The first period and the third period: Sacubitril Alisartan Amlodipine Tablets 240mg/5mg;The second period and the fourth period:Sacubitril Allisartan Calcium Tablets 240mg+Amlodipine Besylate Tablets 5mg

    Drug: Sequence A T-R-T-R

  • Other
    Sequence B R-T-R-T

    The first period and the third period: Sacubitril Allisartan Calcium Tablets 240mg+Amlodipine Besylate Tablets 5mg;The second period and the fourth period: Sacubitril Alisartan Amlodipine Tablets 240mg/5mg

    Drug: Sequence B R-T-R-T

Interventions

  • DrugSequence A T-R-T-R

    The medication sequence for sequence A is as follows: in the first and third cycles, the test formulation (T: Sacubitril Alesartan Amlodipine Tablets) is taken; in the second and fourth cycles, the reference formulation (R: Sacubitril Alesartan Calcium Tablets + Benazepril Amlodipine Tablets) is taken.The administration date should be at least 14 days apart each time.

  • DrugSequence B R-T-R-T

    The administration sequence for sequence B is as follows: in the first and third cycles, the reference formulation (R: sacubitril amlasiatin calcium tablet + benazepril hydrochloride tablet) is administered; in the second and fourth cycles, the test formulation (T: sacubitril amlasiatin and hydrochloride tablet) is administered; each administration date is at least 14 days apart.

06

What researchers measure

Primary outcomes

  1. Cmax of EXP3174、Sacubitril、LBQ657、Amlodipine

    Time frame: through study completion,an average of 47days

  2. AUC0-t of EXP3174、Sacubitril、LBQ657

    Time frame: through study completion,an average of 47days

  3. AUC0-∞of EXP3174、Sacubitril、LBQ657

    Time frame: through study completion,an average of 47days

  4. AUC0-72h of Amlodipine

    Time frame: From 0 o'clock to 72 hours

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Apr 2026, 1 month later.

Of 18 phase 1 interventional studies under Essential Hypertension, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's planned 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2026
First posted
Mar 20, 2026
StartEst.
Mar 9, 2026
Primary completionEst.
Apr 25, 2026
CompletionEst.
Apr 25, 2026
Last update
Mar 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07486453
Responsible party
Sponsor
First posted
Mar 20, 2026
Start date
Mar 9, 2026 (estimated)
Primary completion
Apr 25, 2026 (estimated)
Completion
Apr 25, 2026 (estimated)
Last update
Mar 20, 2026

Study contacts

Huan Zhou, Professor
Contact
zhouhuanbest@vip.163.com
13665527160

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion